Our previous study showed that SR1664 improved established carbon-tetrachloride-induced hepatic fibrosis, suggesting that the antifibrotic effects of PPARγ may be mediated through its non-adipogenic transcriptional activity [12]. The gene discussed is PPARG; the disease is Hepatic fibrosis.